Classification of High‐ and Low‐Risk Patients With Dermal Leiomyosarcoma: An Exploratory Nationwide Cohort Study
Journal of Surgical Oncology · 2026
DOI: 10.1002/jso.70308 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Surgical Oncology, 2026. Verfasst von Kiya Abebe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Leiomyosarcoma, Skin Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Fund of Copenhagen University Hospital Rigshospitalet.
Abstract (Originalsprache)
Background
Risk factors for dermal leiomyosarcoma (dLMS) metastasis remain poorly defined because methodological constraints, small sample sizes, and short follow‐up have limited previous studies.
Objectives
To investigate risk factors for metastasis and local recurrence, and to propose a high‐ and low‐risk classification for dLMS.
Methods
All patients diagnosed with dLMS in Denmark between 1980 and 2022 were included. Absolute 5‑year risks were estimated using the Aalen‐Johansen method, treating all‑cause mortality as a competing risk.
Results
Among 381 patients (median age 66 years, 71% male), the 5‐year risk of metastasis was 2.4% and 10% for local recurrence. The most important risk factors for metastasis were tumor necrosis, mitotic grade 3, and perineural/intravascular invasion, with 5‐year absolute risks ranging between 9% and 25%. Positive surgical margins and perineural/intravascular invasion were associated with increased 5‐year absolute risks of local recurrence, ranging between 26% and 50%.
Conclusion
Although few distant metastases were observed, high‐risk dLMS features may include tumor necrosis, mitotic grade 3, perineural/intravascular invasion, or positive surgical margins. Cases without these features may be classified as low‐risk dLMS. We propose regular cross‐sectional imaging in the follow‐up of patients with high‐risk dLMS, whereas follow‐up for patients with low‐risk dLMS could be limited to clinical examinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Surgery, Helse Fonna, Haugesund Hospital, Haugesund, Norway.
- Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
- Department of Plastic Surgery, Herlev University Hospital, Copenhagen, Denmark.
- Department of Plastic Surgery, Odense University Hospital, Odense, Denmark.
- Department of Orthopedic Surgery, Musculoskeletal Tumor Section, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Mathias Ørholt
Förderung
- Research Fund of Copenhagen University Hospital Rigshospitalet
Zitieren
APA
Abebe, K., Munch, A., Wagenblast, A. L., Schmidt, G., Jensen, D. H., Petersen, M. M., Loya, A. C., Daugaard, S., Mentzel, T., Herly, M., Vester-Glowinski, P., & Ørholt, M. (2026). Classification of High‐ and Low‐Risk Patients With Dermal Leiomyosarcoma: An Exploratory Nationwide Cohort Study. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70308
Vancouver
Abebe K, Munch A, Wagenblast AL, Schmidt G, Jensen DH, Petersen MM, et al. Classification of High‐ and Low‐Risk Patients With Dermal Leiomyosarcoma: An Exploratory Nationwide Cohort Study. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70308
BibTeX
@article{Abebe2026,
author = {Abebe, Kiya and Munch, Anders and Wagenblast, Anne Lene and Schmidt, Grethe and Jensen, David Hebbelstrup and Petersen, Michael M and Loya, Anand C and Daugaard, Søren and Mentzel, Thomas and Herly, Mikkel and Vester-Glowinski, Peter and Ørholt, Mathias},
title = {Classification of High‐ and Low‐Risk Patients With Dermal Leiomyosarcoma: An Exploratory Nationwide Cohort Study},
journal = {Journal of Surgical Oncology},
year = {2026},
doi = {10.1002/jso.70308}
}
EUVIMED